To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Director declaration

Release Date: 01/06/2018 08:00
Code(s): MEI     PDF:  
Wrap Text
Director declaration

Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic” or “the Company”)

1 June 2018

DIRECTOR DECLARATION

Mediclinic, a leading international private healthcare services group, confirms that, as announced on
29 March 2018, Dr Ronnie van der Merwe succeeded Mr Danie Meintjes as Chief Executive Officer
(“CEO”) of the Company with effect from today. Dr Van der Merwe will retain his responsibilities as
Group Chief Clinical Officer until a suitable successor has been identified.

In accordance with Listing Rule 9.6.14R(2), the Company further announces that Mediclinic Jersey
Limited, an indirect wholly-owned subsidiary of the Company and holder of a 29.9% interest in Spire
Healthcare Group plc (“Spire”), has nominated Dr Van der Merwe to be appointed as a non-executive
director of Spire from the conclusion of the Spire annual general meeting held on 24 May 2018.

There are no further disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the UK
Listing Authority's Listing Rules in respect of Dr van der Merwe’s appointment as CEO of the
Company.

About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland,
Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary
healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-
listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities
and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates
49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8
100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more
than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 01/06/2018 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story